CO6210814A2 - Nuevos metodos - Google Patents
Nuevos metodosInfo
- Publication number
- CO6210814A2 CO6210814A2 CO09088171A CO09088171A CO6210814A2 CO 6210814 A2 CO6210814 A2 CO 6210814A2 CO 09088171 A CO09088171 A CO 09088171A CO 09088171 A CO09088171 A CO 09088171A CO 6210814 A2 CO6210814 A2 CO 6210814A2
- Authority
- CO
- Colombia
- Prior art keywords
- disease
- patient
- respiratory
- use according
- decreased
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Otolaryngology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Nutrition Science (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
La invención proporciona métodos para el tratamiento por inhalación de una enfermedad o estado respiratorio en un paciente que necesite dicho tratamiento sin producir en dicho paciente efectos antimuscarínicos sistémicos, comprendiendo administrar a dicho paciente una cantidad eficaz de aclidinio. 1.- Uso de aclidinio, en la fabricación de un medicamento para uso en el tratamiento o prevención de una enfermedad o un estado respiratorio en un paciente por inhalación, sin producir en dicho paciente efectos antimuscarínicos sistémicos. 2.- Uso de acuerdo con la reivindicación 1, en el que la enfermedad respiratoria es una enfermedad que puede ser tratada, mejorada o inhibida por un antagonista de los receptores muscarínicos.3.- Uso de acuerdo con cualquiera de las reivindicaciones precedentes, en el que la enfermedad o el estado respiratorio se selecciona de bronquitis aguda o crónica, enfisema, asma y enfermedad pulmonar obstructiva crónica, especialmente asma y enfermedad pulmonar obstructiva crónica. 4.- Uso de acuerdo con cualquiera de las reivindicaciones precedentes, en el que el paciente sufre o es susceptible de sufrir un estado que puede ser agravado por la actividad antimuscarínica sistémica.5.- Uso de acuerdo con la reivindicación 4, en el que el paciente sufre o es susceptible de sufrir uno o más estados seleccionados de: i. esquizofrenia, disminución de la concentración, confusión, agitación, delirio, falta de atención, disminución de la memoria y depresión respiratoria, ii. glaucoma, xeroftalmía, aumento del tamaño de las pupilas, visión borrosa y aumento de la presión intraocular, iii. próstata dilatada u obstruida y dificultad urinaria, iv. estrechamiento u obstrucción del intestino delgado, colon dilatado, estreñimiento crónico, esófago inferior dilatado, disminución de la motilidad gástrica y estreñimiento, v. xerostomia, irritación de garganta y disminución de la sudación, vi. enfermedad cardiovascular (incluyendo cualquiera de reestenosis, arterioesclerosis, estado previo a un ictus o infarto de miocardio, insuficiencia cardiaca congestiva), arritmia y taquicardia, vii. enfermedad de Parkinson, enfermedad de Alzheimer, demencia, y viii. miastenia grave.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US90284307P | 2007-02-21 | 2007-02-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6210814A2 true CO6210814A2 (es) | 2010-10-20 |
Family
ID=39247776
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO09088171A CO6210814A2 (es) | 2007-02-21 | 2009-08-21 | Nuevos metodos |
Country Status (32)
| Country | Link |
|---|---|
| US (2) | US20110243924A1 (es) |
| EP (1) | EP2120936B1 (es) |
| JP (2) | JP5739616B2 (es) |
| KR (2) | KR20090114401A (es) |
| CN (2) | CN101616670A (es) |
| AR (1) | AR065392A1 (es) |
| AT (1) | ATE513547T1 (es) |
| AU (1) | AU2008217301B2 (es) |
| BR (1) | BRPI0806392A8 (es) |
| CA (1) | CA2678975C (es) |
| CL (1) | CL2008000461A1 (es) |
| CO (1) | CO6210814A2 (es) |
| CY (1) | CY1111799T1 (es) |
| DK (1) | DK2120936T3 (es) |
| EC (1) | ECSP099556A (es) |
| ES (1) | ES2367722T3 (es) |
| HK (1) | HK1132673A1 (es) |
| HR (1) | HRP20110556T1 (es) |
| IL (1) | IL200278A (es) |
| MX (1) | MX2009008825A (es) |
| MY (1) | MY153408A (es) |
| NZ (1) | NZ578473A (es) |
| PE (1) | PE20081789A1 (es) |
| PL (1) | PL2120936T3 (es) |
| PT (1) | PT2120936E (es) |
| RU (1) | RU2484821C2 (es) |
| SI (1) | SI2120936T1 (es) |
| TW (1) | TWI475994B (es) |
| UA (1) | UA98136C2 (es) |
| UY (1) | UY30901A (es) |
| WO (1) | WO2008101591A1 (es) |
| ZA (1) | ZA200904941B (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2165768B1 (es) | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
| EP2100598A1 (en) | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease |
| EP2100599A1 (en) | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease |
| AU2010280497B2 (en) | 2009-08-07 | 2015-10-22 | Generics [Uk] Limited | Anhydrate of tiotropium bromide |
| WO2011095800A2 (en) * | 2010-02-02 | 2011-08-11 | Generics [Uk] Limited | Analytical methods |
| EP2510928A1 (en) | 2011-04-15 | 2012-10-17 | Almirall, S.A. | Aclidinium for use in improving the quality of sleep in respiratory patients |
| US10111957B2 (en) | 2012-07-05 | 2018-10-30 | Arven Ilac Snayi ve Ticaret A.S. | Inhalation compositions comprising glucose anhydrous |
| WO2014007767A1 (en) * | 2012-07-05 | 2014-01-09 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Dry powder inhalers comprising a carrier other than lactose and a ternary component |
| WO2014007771A2 (en) | 2012-07-05 | 2014-01-09 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Inhalation compositions comprising muscarinic receptor antagonist |
| WO2018129434A1 (en) | 2017-01-09 | 2018-07-12 | Gt Biopharma, Inc. | Use and composition for treating myasthenia gravis and other myasthenic syndromes |
| WO2019023318A1 (en) * | 2017-07-25 | 2019-01-31 | Gt Biopharma, Inc. | PHARMACEUTICAL COMPOSITIONS AND METHODS USING PYRIDOSTIGMINE AND AN ANTAGONIST OF NK-1 FOR TREATING SEVERE MYASTHENIA |
| WO2019023175A1 (en) | 2017-07-25 | 2019-01-31 | Gt Biopharma, Inc. | PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE AND NEOSTIGMINE AND AN ANTAGONIST NK-1 FOR THE TREATMENT OF SEVERE MYASTHENIA |
| WO2020014072A1 (en) * | 2018-07-09 | 2020-01-16 | Gt Biopharma, Inc. | Neostigmine pharmaceutical combination for treating myasthenia gravis |
| JP7104449B2 (ja) | 2020-05-20 | 2022-07-21 | シンテカバイオ インコーポレイティッド | 二類重症急性呼吸器症候群コロナウイルス感染症の予防または治療用組成物 |
| KR102169476B1 (ko) * | 2020-05-20 | 2020-10-23 | (주)신테카바이오 | 제2형 중증급성호흡기증후군 코로나바이러스 감염 질환의 예방 또는 치료용 조성물 |
| CN115267024B (zh) * | 2022-07-31 | 2023-06-30 | 浙江知一药业有限责任公司 | 治疗呼吸系统疾病的药物组合物及其检测方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2165768B1 (es) * | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
| US20050026948A1 (en) * | 2003-07-29 | 2005-02-03 | Boehringer Ingelheim International Gmbh | Medicaments for inhalation comprising an anticholinergic and a betamimetic |
| DE102004016179A1 (de) | 2004-03-30 | 2005-10-20 | Boehringer Ingelheim Pharma | Verbindungen zur Behandlung von proliferativen Prozessen |
| ES2257152B1 (es) | 2004-05-31 | 2007-07-01 | Laboratorios Almirall S.A. | Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos. |
-
2008
- 2008-01-31 NZ NZ578473A patent/NZ578473A/en unknown
- 2008-01-31 KR KR1020097017243A patent/KR20090114401A/ko not_active Application Discontinuation
- 2008-01-31 CA CA2678975A patent/CA2678975C/en active Active
- 2008-01-31 UA UAA200909464A patent/UA98136C2/ru unknown
- 2008-01-31 RU RU2009135078/15A patent/RU2484821C2/ru active
- 2008-01-31 DK DK08707469.6T patent/DK2120936T3/da active
- 2008-01-31 BR BRPI0806392A patent/BRPI0806392A8/pt not_active Application Discontinuation
- 2008-01-31 ES ES08707469T patent/ES2367722T3/es active Active
- 2008-01-31 PL PL08707469T patent/PL2120936T3/pl unknown
- 2008-01-31 SI SI200830381T patent/SI2120936T1/sl unknown
- 2008-01-31 PT PT08707469T patent/PT2120936E/pt unknown
- 2008-01-31 AU AU2008217301A patent/AU2008217301B2/en active Active
- 2008-01-31 MX MX2009008825A patent/MX2009008825A/es active IP Right Grant
- 2008-01-31 MY MYPI20093444A patent/MY153408A/en unknown
- 2008-01-31 CN CN200880005871A patent/CN101616670A/zh active Pending
- 2008-01-31 WO PCT/EP2008/000782 patent/WO2008101591A1/en active Application Filing
- 2008-01-31 CN CN201510633145.XA patent/CN105395548A/zh active Pending
- 2008-01-31 US US12/528,267 patent/US20110243924A1/en not_active Abandoned
- 2008-01-31 EP EP08707469A patent/EP2120936B1/en active Active
- 2008-01-31 KR KR20157007787A patent/KR20150038750A/ko not_active Application Discontinuation
- 2008-01-31 JP JP2009550665A patent/JP5739616B2/ja active Active
- 2008-01-31 AT AT08707469T patent/ATE513547T1/de active
- 2008-02-07 UY UY0001030901A patent/UY30901A/es unknown
- 2008-02-13 CL CL200800461A patent/CL2008000461A1/es unknown
- 2008-02-20 AR ARP080100680A patent/AR065392A1/es unknown
- 2008-02-20 PE PE2008000361A patent/PE20081789A1/es not_active Application Discontinuation
- 2008-02-20 TW TW097105887A patent/TWI475994B/zh not_active IP Right Cessation
-
2009
- 2009-07-15 ZA ZA2009/04941A patent/ZA200904941B/en unknown
- 2009-08-04 EC EC2009009556A patent/ECSP099556A/es unknown
- 2009-08-06 IL IL200278A patent/IL200278A/en active IP Right Grant
- 2009-08-21 CO CO09088171A patent/CO6210814A2/es not_active Application Discontinuation
-
2010
- 2010-01-05 HK HK10100031.9A patent/HK1132673A1/xx unknown
-
2011
- 2011-07-26 HR HR20110556T patent/HRP20110556T1/hr unknown
- 2011-08-31 CY CY20111100836T patent/CY1111799T1/el unknown
-
2013
- 2013-12-05 JP JP2013252283A patent/JP2014062114A/ja active Pending
-
2014
- 2014-12-05 US US14/561,857 patent/US20150093374A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6210814A2 (es) | Nuevos metodos | |
| CN101084195B (zh) | 作为5-ht2a血清素受体调节剂适用于治疗与其相关的病症的3-苯基-吡唑衍生物 | |
| Nasrallah et al. | Successful treatment of clozapine-nonresponsive refractory hallucinations and delusions with pimavanserin, a serotonin 5HT-2A receptor inverse agonist | |
| US9187430B2 (en) | Poly (ADP-ribose) polymerase inhibitor | |
| CN106061956A (zh) | 作为RORγ调节剂的杂环砜 | |
| CN105085482B (zh) | 取代的哌嗪化合物及其使用方法和用途 | |
| CN101686989A (zh) | 取代的咪唑并杂环 | |
| TW200918073A (en) | Heterocyclus-substituted piperazino-dihydrothienopyrimidines | |
| EA200701704A1 (ru) | Аналоги и гибридные полипептиды gip с избираемыми свойствами | |
| US11919858B2 (en) | Aminonapthoquinone compounds and pharmaceutical composition for blocking ubiquitination-proteasome system in diseases | |
| CN106883194A (zh) | 噁二唑类衍生物、其制备方法及其在医药上的应用 | |
| WO2006131392A8 (en) | Pharmaceutical compositions of a neuroactive steroid and uses thereof | |
| NO20073566L (no) | Oksyindol-derivater som agonister for 5HT4-reseptor | |
| IN2012DN02590A (es) | ||
| JP2020517611A (ja) | アミノピリジン誘導体化合物の塩、その結晶形態、及びその調製プロセス | |
| TW200900072A (en) | Soluble epoxide hydrolase inhibitors | |
| CN104513235A (zh) | 取代的氨基嘧啶类化合物及其使用方法和用途 | |
| JPWO2017111005A1 (ja) | １−（３−（２−（１−ベンゾチオフェン−５−イル）エトキシ）プロピル）アゼチジン−３−オールまたはその塩を含む錠剤 | |
| CN103316000A (zh) | 用作rock抑制剂的杂环酰胺 | |
| US20170240521A1 (en) | Peripherally-acting cannabinoid receptor agonists for chronic pain | |
| US20220081417A1 (en) | Substituted pyridine derivatives as sarm1 inhibitors | |
| US20200270214A1 (en) | NADPH Oxidase Inhibitors and Uses Thereof | |
| TW200510341A (en) | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them | |
| MX2009007610A (es) | Heterociclicos biciclicos, medicamentos que contienen estos compuestos, su utilizacion y procedimientos para su preparacion. | |
| TW420675B (en) | N-substituted azaheterocyclic compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Application refused |